Correlation Between Aerovate Therapeutics and Lyell Immunopharma

Can any of the company-specific risk be diversified away by investing in both Aerovate Therapeutics and Lyell Immunopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aerovate Therapeutics and Lyell Immunopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Aerovate Therapeutics and Lyell Immunopharma, you can compare the effects of market volatilities on Aerovate Therapeutics and Lyell Immunopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aerovate Therapeutics with a short position of Lyell Immunopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aerovate Therapeutics and Lyell Immunopharma.

Diversification Opportunities for Aerovate Therapeutics and Lyell Immunopharma

-0.06

Correlation Coefficient

Aerovate Therapeutics  Lyell Immunopharma

Good diversification

The 3 months correlation between Aerovate and Lyell is -0.06. Overlapping area represents the amount of risk that can be diversified away by holding Aerovate Therapeutics and Lyell Immunopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lyell Immunopharma and Aerovate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aerovate Therapeutics are associated (or correlated) with Lyell Immunopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lyell Immunopharma has no effect on the direction of Aerovate Therapeutics i.e., Aerovate Therapeutics and Lyell Immunopharma go up and down completely randomly.

Pair Corralation between Aerovate Therapeutics and Lyell Immunopharma

Given the investment horizon of 90 days Aerovate Therapeutics is expected to generate 0.47 times more return on investment than Lyell Immunopharma. However, Aerovate Therapeutics is 2.14 times less risky than Lyell Immunopharma. It trades about 0.1 of its potential returns per unit of risk. Lyell Immunopharma is currently generating about -0.08 per unit of risk. If you would invest  212.00  in Aerovate Therapeutics on October 25, 2024 and sell it today you would earn a total of  38.00  from holding Aerovate Therapeutics or generate 17.92% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Aerovate Therapeutics  vs.  Lyell Immunopharma

Aerovate Therapeutics

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Aerovate Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of rather fragile basic indicators, Aerovate Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

Lyell Immunopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Lyell Immunopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in February 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with Aerovate Therapeutics and Lyell Immunopharma

The main advantage of trading using opposite Aerovate Therapeutics and Lyell Immunopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aerovate Therapeutics position performs unexpectedly, Lyell Immunopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyell Immunopharma will offset losses from the drop in Lyell Immunopharma's long position.

The idea behind Aerovate Therapeutics and Lyell Immunopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.